Almirall, Barcelona Supercomputing Center team up to apply AI in dermatology drug discovery

By Public Technologies
  • Almirall announced a three-year R&D collaboration with Barcelona Supercomputing Center to accelerate dermatology drug discovery using AI and high-performance computing.
  • Work will target new therapeutic targets, AI-driven drug design, molecular-level disease research, and synthetic data to support precision medicine in skin diseases.
  • Program will apply digital skin twins to model rare dermatological conditions, aiming to speed development timelines, cut research costs, and reduce animal testing.
  • Four BSC life-science research groups will support the effort across genomics, computational biology, molecular modeling, and machine learning.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Almirall SA published the original content used to generate this news brief on September 16, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.